Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Action inhibitors, antagonists |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Phase 1 | United States | 30 Jan 2022 | |
Wet age-related macular degeneration | Preclinical | United States | 30 Jan 2022 |